Oncocyte (NASDAQ:IMDX – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.19) earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $0.56 million for the quarter.
Here are the key takeaways from Oncocyte’s conference call:
- The FDA said the clinical data in the initial GraftAssureDx submission did not yet support the proposed intended use and requested additional evidence, including an independent accuracy study and expert biopsy-slide reviews. The company expects to submit its response before the January 21, 2027 deadline, but authorization and U.S. launch timing remain dependent on FDA review.
- Insight has begun enrolling patients in its GALACTIC registry, with about five sites expected to be enrolling by year-end, and says beta-site comparisons have shown performance equivalent to legacy tests. Management expects the registry and beta program to generate some revenue and increase clinical familiarity, while cautioning that near-term revenue will be modest.
- The company said transplant centers representing slightly more than 5% of U.S. kidney transplants are committed to developing in-house testing and could launch in 2027. Initial commercialization would focus on larger centers in MolDX jurisdictions, though broader uptake depends on local validation and reimbursement.
- Operating expenses declined from their Q4 2025 peak, with R&D expense at $3.8 million in Q3 versus $5.8 million at the peak; management said operating expenses excluding non-cash items were flat year over year. It also said free cash flow improved and that the FDA-related spending burden is winding down.
- Insight added urine testing for T-cell-mediated rejection to its pipeline and is pursuing heart-transplant testing, with a possible heart submission in the second half of 2027. It also expects to submit kidney and heart applications in Europe around year-end or early January, but said limited reimbursement there currently constrains commercialization.
Oncocyte Trading Down 10.2%
Oncocyte stock traded down $0.18 during midday trading on Wednesday, hitting $1.60. 102,009 shares of the stock were exchanged, compared to its average volume of 235,551. The stock’s 50-day simple moving average is $3.20 and its 200 day simple moving average is $4.50. Oncocyte has a fifty-two week low of $1.63 and a fifty-two week high of $7.51. The stock has a market capitalization of $52.29 million, a price-to-earnings ratio of -1.28 and a beta of 1.90.
Analysts Set New Price Targets
View Our Latest Research Report on Oncocyte
Oncocyte Company Profile
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Read More
- Five stocks we like better than Oncocyte
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
